【摘要】 目的    探讨α-辛酸(ALA)对不同程度糖尿病慢性肾脏疾病(CKD)患者尿足细胞标志蛋白(PCX)及VEGF的影响。 方法   186例T2DM患者根据UAER分为单纯糖尿病组(SDM组)、尿白蛋白微量组(NA组)、尿白蛋白大量组(MA组)，NA组和MA组又分为ALA治疗组(NA工组，MA I组)及常规治疗组(NAⅡ组，MAlI组)。另选正常对照者(NC组)60名。比较各组ALA治疗前及治疗2周后尿PCX及血VEGF。结果    NAI组ALA治疗后PCX[(17.65±3.05)vs(7.28±2.93)/ug/L，P<0.01]，VEGF[(453.94±36.17)VS(356.39±47.08)ng/L，P<001]下降，MA I组ALA治疗后PCX[(265±51)vs(119.9±2.22)pg/L，P<0.01]，VEGF[(550.65±46.76)vs(397.69±44.74)ng/L，P
d0.01)]下降。 结论   ALA可通过抗氧化应激(0S)保护肾小球足细胞。
      【关键词】 糖尿病慢性肾脏疾病；α-硫辛酸；尿足细胞标志蛋白；血管内皮生长因子

      【Abstract】  Objective   To investigate the effect of α-lipoic acid(ALA)On urinary podocalyxin (PCX)and vascular endothelial growth factor(VEGF)in different stages of chronic kidney disease(CKD) in diabetes． Methods    A total of 246 participants were divided into four groups according tO their UAER：normal control group(NC，n=60)，simple diabetes mellitus without nephropathy group(SDM，n=62)，micro albuminuria group(NA，n=60)and macro albuminuria group(MA，n=64)．NA and MA groups were also randomly divided into two groups：ALA treatment group(NA I，MA I)and conventional treatment group(NAⅡ，MA 1I)．The 1evels of urinary PCX and serum VEGF were determined at baseline and after 2 weeks’treatment． Results The levels of urinary PCX and serum VEGF were 10wer after ALA treatment than before ALA treatment in NA I[(17.65±3.05)vs(7.28±2.93) μg／L(453.94±36.17)vs (356.39±47.08) ng／L；P<0.01] and MA I[(26.95±5.41)vs(11.99±2.22)μg/L；(550.654±46.76) vs (397.69±44.74)ng/L，P<0.01)]groups respectively． Conclusion    ALA can protect glomerular podocyte from injury，possibly due to its effects on alleviating enhancedoxidative stress(OS)．
      【Key words】 Chronic kidney disease(CKD)in diabetes；α-lipoic acid(ALA)；Urinary podocalyxin
(PCX)：Vascular endothelial growth factor(VDGF)